Modeling high-grade serous ovarian carcinogenesis from the fallopian tube

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 18, 2011, Pages 7547-7552

  Karst, Alison M ^a   Levanon, Keren ^a,c,d   Drapkin, Ronny ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d Chaim Shema Medical Center   (Israel)

Author keywords

Cell of origin; Fimbria; Secretory cell; TP53

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GRADING; CANCER MODEL; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TRANSFORMATION; CLONOGENESIS; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MULLERIAN CARCINOMA; ONCOGENE C MYC; ONCOGENE H RAS; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SECRETORY CELL; SIMIAN VIRUS 40; TUMOR XENOGRAFT; UTERINE TUBE;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; BLOTTING, WESTERN; CARCINOGENICITY TESTS; CARCINOMA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COMPARATIVE GENOMIC HYBRIDIZATION; EPITHELIAL CELLS; FALLOPIAN TUBES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; OVARIAN NEOPLASMS; TELOMERASE; TUMOR STEM CELL ASSAY;

EID: 79956313481     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1017300108     Document Type: Article

References (37)

1. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
2. Bast RC, Jr., Hennessy B, Mills GB (2009) The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 9:415-428.
3. Seidman JD, et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23:41-44. (Pubitemid 38018236)
4. Karst AM, Drapkin R (2010) Ovarian cancer pathogenesis: A model in evolution. J Oncol 2010:932371.
5. Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26:5284-5293.
6. Vang R, Shih IeM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267-282.
7. Malpica A, et al. (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496-504. (Pubitemid 38436523)
8. Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 34:433-443.
9. Landen CN Jr., Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26:995-1005. (Pubitemid 351398093)
10. Lynch HT, et al. (2009) Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3:97-137.
11. Dubeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197.
12. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34:1407-1416.
13. Crum CP (2009) Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol Oncol 3:165-170.
14. Medeiros F, et al. (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230-236. (Pubitemid 43740193)
15. Lee Y, et al. (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26-35. (Pubitemid 46092026)
16. Kindelberger DW, et al. (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31:161-169. (Pubitemid 46175016)
17. Folkins AK, et al. (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168-173.
18. Levanon K, et al. (2010) Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29:1103-1113.
19. Bowen NJ, et al. (2007) Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 104:331-337. (Pubitemid 46135661)
20. Hahn WC, et al. (1999) Creation of human tumour cells with defined genetic elements. Nature 400:464-468. (Pubitemid 29361801)
21. Ali SH, DeCaprio JA (2001) Cellular transformation by SV40 large T antigen: Interaction with host proteins. Semin Cancer Biol 11:15-23.
22. Karnoub AE, Weinberg RA (2008) Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol 9:517-531. (Pubitemid 351881844)
23. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z (2009) High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2:21.
24. Darcy KM, et al. (2009) Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecol Oncol 114:472-479.
25. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D (2006) Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer 42:674-679. (Pubitemid 43343691)
26. Rane SG, Cosenza SC, Mettus RV, Reddy EP (2002) Germ line transmission of the Cdk4 (R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 22:644-656. (Pubitemid 34027508)
27. Chen W, et al. (2004) Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5:127-136. (Pubitemid 38283799)
28. Kuo KT, et al. (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036-4042.
29. Gorringe KL, et al.; Australian Ovarian Cancer Study (2010) Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE 5: e11408.
30. Nowee ME, et al. (2007) DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 213:46-55.
31. Laury AR, et al. (2010) PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34:627-635.
32. Madore J, et al. (2010) Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 220:392-400.
33. Sasaki R, et al. (2009) Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 30:423-431.
34. Liu J, et al. (2004) A genetically defined model for human ovarian cancer. Cancer Res 64:1655-1663. (Pubitemid 38428686)
35. Zheng J, et al. (2010) Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 9:140-146.
36. Khalil I, Brewer MA, Neyarapally T, Runowicz CD (2010) The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. Gynecol Oncol 116:282-285.
37. Ramakrishna M, et al. (2010) Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS ONE 5: e9983.